Annexon biosciences reports second quarter 2021 financial results and provides mid-year business update

– recently expanded autoimmune franchise with advancement of third clinical candidate, anx009, and strategically expanded into additional autoantibody-driven diseases –

ANNX Ratings Summary

ANNX Quant Ranking